Therapeutic targeting of mutated p53 in acute lymphoblastic leukemia.
作者信息
van Leeuwen Frank N
机构信息
Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
出版信息
Haematologica. 2020 Jan;105(1):10-11. doi: 10.3324/haematol.2019.234872.
Abstract
摘要
相似文献
1
Therapeutic targeting of mutated p53 in acute lymphoblastic leukemia.急性淋巴细胞白血病中突变型p53的治疗靶向作用
Haematologica. 2020 Jan;105(1):10-11. doi: 10.3324/haematol.2019.234872.
2
p16: at last a tumor suppressor gene involved in childhood acute lymphoblastic leukemias!p16：终于发现了一个与儿童急性淋巴细胞白血病相关的肿瘤抑制基因！
Pediatr Hematol Oncol. 1997 Mar-Apr;14(2):iii-viii. doi: 10.3109/08880019709030892.
3
TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy.TP53突变在复发性融合基因阴性的成人急性淋巴细胞白血病病例中很常见，并且与诱导治疗反应不佳相关。
Haematologica. 2013 May;98(5):e59-61. doi: 10.3324/haematol.2012.076786. Epub 2013 Feb 12.
4
Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome.成人治疗相关B细胞急性淋巴细胞白血病具有独特的基因特征，常伴有TP53缺失且预后较差。
Leukemia. 2021 Jul;35(7):2097-2101. doi: 10.1038/s41375-020-01061-9. Epub 2020 Oct 21.
5
MYC Expression Is Associated With p53 Expression and TP53 Aberration and Predicts Poor Overall Survival in Acute Lymphoblastic Leukemia/Lymphoma.MYC 表达与 p53 表达和 TP53 异常相关，并预测急性淋巴细胞白血病/淋巴瘤患者总体生存不良。
Am J Clin Pathol. 2022 Jan 6;157(1):119-129. doi: 10.1093/ajcp/aqab105.
6
Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia.小儿急性淋巴细胞白血病中突变型p53的治疗靶点
Haematologica. 2020 Jan;105(1):170-181. doi: 10.3324/haematol.2018.199364. Epub 2019 May 9.
7
p53 expression and poor prognosis in childhood acute lymphoblastic leukemia.p53表达与儿童急性淋巴细胞白血病的不良预后
Anticancer Res. 1994 Nov-Dec;14(6B):2759-61.
8
Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia.体细胞TP53突变是急性淋巴细胞白血病中的白血病前期事件。
Blood. 2023 Mar 30;141(13):1640-1644. doi: 10.1182/blood.2022017249.
9
Does TP53 guard ALL genomes?TP53 守护所有基因组吗？
Blood. 2014 Jul 10;124(2):160-1. doi: 10.1182/blood-2014-05-576934.
10
[Abnormal expression of hMSH2 mRNA and mutation P53 protein in acute lymphoblastic leukemia].急性淋巴细胞白血病中hMSH2 mRNA的异常表达及P53蛋白的突变
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005 Dec;13(6):948-50.
引用本文的文献
1
Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignancies.WD 重复结构域 5 抑制剂的扩展分析揭示了治疗血液系统恶性肿瘤的可行策略。
Proc Natl Acad Sci U S A. 2024 Aug 27;121(35):e2408889121. doi: 10.1073/pnas.2408889121. Epub 2024 Aug 21.
2
Constitutively active CaMKII Drives B lineage acute lymphoblastic leukemia/lymphoma in tp53 mutant zebrafish.组成性激活的 CaMKII 在 tp53 突变的斑马鱼中驱动 B 细胞急性淋巴细胞白血病/淋巴瘤。
PLoS Genet. 2023 Dec 20;19(12):e1011102. doi: 10.1371/journal.pgen.1011102. eCollection 2023 Dec.
3
miR-16-5p enhances sensitivity to RG7388 through targeting expression (WIP1) in Childhood Acute Lymphoblastic Leukemia.微小RNA-16-5p通过靶向儿童急性淋巴细胞白血病中的野生型p53诱导磷酸酶1（WIP1）表达增强对RG7388的敏感性。
Cancer Drug Resist. 2023 Apr 29;6(2):242-256. doi: 10.20517/cdr.2022.113. eCollection 2023.
4
Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells.突变型 p53 激活化合物 APR-246 与天冬酰胺酶协同作用，诱导急性淋巴细胞白血病细胞生长抑制。
Cell Death Dis. 2021 Jul 15;12(7):709. doi: 10.1038/s41419-021-03988-y.
本文引用的文献
1
Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia.小儿急性淋巴细胞白血病中突变型p53的治疗靶点
Haematologica. 2020 Jan;105(1):170-181. doi: 10.3324/haematol.2018.199364. Epub 2019 May 9.
2
APR-246/PRIMA-1 inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.APR-246/PRIMA-1抑制硫氧还蛋白还原酶1，并将该酶转化为一种特定的NADPH氧化酶。
Cell Death Dis. 2017 Apr 13;8(4):e2751. doi: 10.1038/cddis.2016.137.
3
Mutations in Hypodiploid Acute Lymphoblastic Leukemia.亚二倍体急性淋巴细胞白血病中的突变
Cold Spring Harb Perspect Med. 2017 Mar 1;7(3):a026286. doi: 10.1101/cshperspect.a026286.
4
The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.TP53 突变和缺失对 AML、ALL、MDS 和 CLL 患者生存的影响不同：对 3307 例病例的分析。
Leukemia. 2017 Mar;31(3):705-711. doi: 10.1038/leu.2016.263. Epub 2016 Sep 29.
5
Clinical Overview of MDM2/X-Targeted Therapies.MDM2/X靶向疗法的临床概述
Front Oncol. 2016 Jan 27;6:7. doi: 10.3389/fonc.2016.00007. eCollection 2016.
6
p53 in survival, death and metabolic health: a lifeguard with a licence to kill.p53 在生存、死亡和代谢健康中的作用：有杀人执照的救生员。
Nat Rev Mol Cell Biol. 2015 Jul;16(7):393-405. doi: 10.1038/nrm4007.
7
Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.TP53 基因突变和缺失可预测儿童急性淋巴细胞白血病首次复发时治疗无反应和预后不良。
J Clin Oncol. 2011 Aug 10;29(23):3185-93. doi: 10.1200/JCO.2011.34.8144. Epub 2011 Jul 11.
8
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.PRIMA-1通过与核心结构域共价结合来重新激活突变型p53。
Cancer Cell. 2009 May 5;15(5):376-88. doi: 10.1016/j.ccr.2009.03.003.
9
The antioxidant function of the p53 tumor suppressor.p53肿瘤抑制因子的抗氧化功能。
Nat Med. 2005 Dec;11(12):1306-13. doi: 10.1038/nm1320. Epub 2005 Nov 13.
10
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.一种低分子量化合物使突变型p53的肿瘤抑制功能得以恢复。
Nat Med. 2002 Mar;8(3):282-8. doi: 10.1038/nm0302-282.
Zotero 插件